logo-loader
viewProtomer Technologies Inc.

Protomer Technologies developing an insulin injectable alternative for diabetes patients

Protomer Technologies Inc CEO Alborz Mahdavi joined Proactive at the Biotech Showcase 2020 in San Francisco. The California-based, privately-held biotechnology company is developing a glucose responsive insulin that can automatically adjust its activity in the body throughout the day.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Rakuten Medical receives conditional approval in Japan for head and neck...

Rakuten Medical, Inc VP of Global Regulatory Peggy Berry tells Proactive the California-based biotechnology group has received conditional early approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW). Berry says the privately-held group's lead drug ASP-1929, which aims to...

15 hours, 14 minutes ago

2 min read